Hikal Ltd
NSE:HIKAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hikal Ltd
NSE:HIKAL
|
IN |
Hikal Ltd
Hikal Ltd. engages in the manufacture of chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities. The company is headquartered in Navi Mumbai, Maharashtra. The Company’s operating segments include the crop protection and pharmaceuticals space. The Crop protection produce and trades in pesticides and herbicides. Its facilities are in Taloja, Mahad (Maharashtra), and Panoli (Gujarat). The Pharmaceuticals space produce and trades in active pharmaceuticals ingredients. Its facilities are in Jigani (Bengaluru) and Panoli (Gujarat). The Company’s products and services include gabapentin, thiabendazole, and diuron contract development and custom manufacturing of intermediates, application programming interface (APIs), and artificial intelligence (AI’s). The company offers solutions to route scouting, process development, analytical method development, technology development, process engineering, scale-up support, and small-scale synthesis.
Hikal Ltd. engages in the manufacture of chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities. The company is headquartered in Navi Mumbai, Maharashtra. The Company’s operating segments include the crop protection and pharmaceuticals space. The Crop protection produce and trades in pesticides and herbicides. Its facilities are in Taloja, Mahad (Maharashtra), and Panoli (Gujarat). The Pharmaceuticals space produce and trades in active pharmaceuticals ingredients. Its facilities are in Jigani (Bengaluru) and Panoli (Gujarat). The Company’s products and services include gabapentin, thiabendazole, and diuron contract development and custom manufacturing of intermediates, application programming interface (APIs), and artificial intelligence (AI’s). The company offers solutions to route scouting, process development, analytical method development, technology development, process engineering, scale-up support, and small-scale synthesis.
Revenue Recovery: Hikal reported consolidated Q3 FY '26 revenue of INR 494 crores, reflecting a return to operational profitability after recent regulatory and operational challenges.
Pharma Momentum: The Pharmaceutical segment saw strong sequential improvement, with Q3 revenue of INR 337 crores and an EBIT margin of 12.3%. Remediation from the US FDA audit is nearly complete, and further growth is expected in Q4.
Crop Protection Pressure: The Crop Protection segment remains under margin pressure due to global overcapacity and pricing competition, especially from China, with Q3 revenue of INR 157 crores and an EBIT margin of 3%.
Guidance Update: Double-digit growth in Pharma for FY '26 is now delayed to next year due to earlier FDA-related disruptions. Crop Protection is expected to remain flat year-over-year.
Strategic Diversification: Hikal is expanding into Animal Health and Personal Care, expecting these segments to become meaningful revenue contributors over the next 2-4 years.
CapEx & Cost Control: CapEx for the year has been revised down to INR 150 crores from earlier guidance of INR 200 crores. Debt and working capital are being tightly managed.
Positive Outlook: Management believes the worst is behind, with Q4 expected to show further improvement and FY '27 positioned for robust, higher-margin growth.
